RxDoctor Payments Data

Muhammad Alam, MD

Internal Medicine · Fresno, CANPI 1417906835

Payments from drug & device makers

$158,267in general payments, 2019–2025

Across 919 payments — averaging $172.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$55K
  • Boehringer Ingelheim$40K
  • E.r. Squibb & Sons, L.L.C.$27K
  • Eli Lilly$5K
  • AbbVie$4K
  • Bristol Myers Squibb$3K
  • plus $24K from 54 others

What the payments were for

  • Consulting fees$26,10023%
  • Speaking & faculty fees$57,59451%
  • Travel & lodging$12,61411%
  • Food & beverage$15,60014%
  • Education$1,0441%
  • Other$1,0801%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen76$54,666
Boehringer Ingelheim21$40,157
E.r. Squibb & Sons, L.L.C.153$27,366
Eli Lilly21$5,187
AbbVie17$3,884
Bristol Myers Squibb11$3,167
Boehringer Ingelheim Pharma GmbH & Co.kg14$2,558
GSK29$2,452
Novartis86$2,450
Pfizer58$2,283
Boehringer Ingelheim International GmbH7$1,872
AstraZeneca(2 entities)41$1,489
Bayer7$1,052
Sanofi8$956
Daiichi Sankyo Inc.30$781
Johnson & Johnson(2 entities)49$723
Astellas Pharma US Inc24$613
Lilly USA, LLC13$543
Merck27$513
Exelixis Inc.20$443
Incyte Corporation9$365
Octapharma USA, Inc.10$337
AVEO Pharmaceuticals, Inc.9$311
Genentech USA, Inc.21$277
Takeda Pharmaceuticals U.S.A., Inc.18$277
Sobi, Inc10$227
Seagen Inc.5$216
Eisai Inc.10$213
Array Biopharma Inc11$213
Pharmaessentia USA Corporation8$189
Regeneron Healthcare Solutions, Inc.6$185
Pharmacyclics LLC, An Abbvie Company5$179
Tesaro, Inc.3$152
Gilead7$152
Stemline Therapeutics Inc.5$150
Tersera Therapeutics LLC6$144
Novo Nordisk1$125
Ipsen Biopharmaceuticals, Inc6$120
Springworks Therapeutics, Inc.4$107
Caris MPI, Inc.4$95
Puma Biotechnology, Inc.3$67
Beigene USA, Inc.4$66
Dova Pharmaceuticals3$58
Tempus AI, Inc3$57
Agios Pharmaceuticals, Inc.2$51
Tactile Systems Technology Inc1$49
Taiho Oncology, Inc.2$48
Karyopharm Therapeutics Inc.2$48
Geron Corporation2$47
Verity Pharmaceuticals Inc.2$47
Servier Pharmaceuticals LLC2$41
Sumitomo Pharma America, Inc.2$40
Apellis Pharmaceuticals, Inc.2$38
Myriad Genetic Laboratories, Inc.1$37
Medtronic1$35
Immunocore Limited1$34
Kyowa Kirin, Inc.2$32
Iovance Biotherapeutics, Inc.1$28
Rigel Pharmaceuticals, Inc.1$26
Accord Healthcare, Inc.1$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$158,267 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$1,410,907
Medicare patients
480
Services billed
66,943

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZejulaNiraparib Tosylate24$673,802
RevlimidLenalidomide13$225,967
WeliregBelzutifan12$225,070
XtandiEnzalutamide18$206,502
SprycelDasatinib11$193,119
IbrancePalbociclib12$189,830
Lenalidomide13$167,957
EliquisApixaban94$63,233
XareltoRivaroxaban26$19,498
ClinisolParenteral Amino Acid 15% No.555$18,913
Abiraterone Acetate14$11,954
CreonLipase/Protease/Amylase14$6,137
Megestrol Acetate24$2,269
Ondansetron OdtOndansetron64$2,104
Anastrozole65$1,599

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKZejula$2,452$673,80224 claims
PfizerIbrance, Eliquis$2,283$253,063106 claims
Bristol Myers SquibbRevlimid$3,167$225,96713 claims
MerckWelireg$513$225,07012 claims
Astellas Pharma US IncXtandi$613$206,50218 claims
E.r. Squibb & Sons, L.L.C.Sprycel$27,366$193,11911 claims
Johnson & JohnsonXarelto$723$19,49826 claims
AbbVieCreon$3,884$6,13714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →